Seronegative spondylarthropathy: Variable manifestations, common characteristics;Seronegatieve spondylartropathie: Variabele verschijningsvormen, gemeenschappelijke kenmerken

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 25, 2007, Pages 1377-1381

  Van Rijthouen, A W A M ^a   Jacobs, J W G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B ANTIGEN; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; HLA B27 ANTIGEN; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; SEROLOGY; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; IMMUNOLOGY; PATHOLOGY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HLA-B27 ANTIGEN; HUMANS; MALE; METHOTREXATE; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447283279     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lu DW, Katz KA. Declining use of the eponym 'Reiter's syndrome' in the medical literature, 1998-2003. J Am Acad Dermatol. 2005;53:720-3.
2. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum. 1995;38:845-50.
3. Dougados M, Linden S van der, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-27.
4. Heuft-Dorenbosch L, Landewe R, Weijers R, Houben H, Linden S van der, Jacobs P, et al. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis. 2007;66:92-8.
5. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52:1000-8.
6. Jacobs JW, Vugt RM van, Swen WA. Echografie in de reumatologische praktijk. Ned Tijdschr Geneeskd. 2005;149:1730-8.
7. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis. 2006;65(Suppl 3):iii22-4.
8. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol. 1976;5:60-4.
9. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756-65.
10. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42:2325-9.
11. Fraser AD, Kuijk AW van, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64.
12. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50.
13. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis [Cochrane review]. Cochrane Database Syst Rev. 2006;4:CD004524.
14. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol. 1993;32:729-33.
15. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol. 1991;10:43-8.
16. Corkill MM, Jobanputra P, Gibson T, Macfarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol. 1990;29:41-5.
17. Denderen JC van, Paardt M van der, Nurmohamed MT, Ryck YM de, Dijkmans BA, Horst-Bruinsma IE van der. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2005;64:1761-4.
18. Braun J, Landewé R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646-52.
19. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Successful short term treatment of patients with severe undifferentiated spondylarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol. 2004;31:531-8.
20. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol. 2002;29:118-22.
21. Bos WE, Thio HB, Neumann HA, Fits L van der, Prens EP. Nieuwe systemische behandelingen bij psoriasis: etanercept, infliximab, adalimumab, efalizumab en alefacept. Ned Tijdschr Geneeskd. 2006;150:1065-70.
22. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447-51.